# Arovella Therapeutics Ltd: Phase 1 study started recruiting, 46 planned (Non Hodgkin Lymphoma (NHL), Leukaemia)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Arovella Therapeutics Ltd |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. |
| NCT ID | NCT07518329 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Non Hodgkin Lymphoma (NHL); Leukaemia |
| Intervention types | drug |
| Target enrollment | 46 |
| Site countries | Australia |
| Posted | 2026-04-08 |
| Planned start | 2026-10-19 |
| Event | Started recruiting |
| Event date | 2026-10-19 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07518329). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.